Role of Lipocalin-2 in N1/N2 Neutrophil Polarization After Stroke.

IF 2.7 4区医学 Q3 NEUROSCIENCES

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI:10.2174/1871527322666230417112850

Zhiliang Guo, Guoli Xu, Jiaping Xu, Yaqian Huang, Chunfeng Liu, Yongjun Cao

{"title":"Role of Lipocalin-2 in N1/N2 Neutrophil Polarization After Stroke.","authors":"Zhiliang Guo, Guoli Xu, Jiaping Xu, Yaqian Huang, Chunfeng Liu, Yongjun Cao","doi":"10.2174/1871527322666230417112850","DOIUrl":null,"url":null,"abstract":"Background: Neutrophils and Lipocalin-2 (LCN2) play pivotal roles in cerebral ischemiareperfusion (I/R) injury. However, their contribution is not fully clarified.Objective: This study aimed to explore the role of LCN2 and its association with neutrophil polarization in I/R injury.Methods: A mouse model of middle cerebral artery occlusion (MCAO) was used to induce cerebral ischemia. LCN2mAb was administered 1 h and Anti-Ly6G was administered for 3d before MCAO. The role of LCN2 in the polarity transition of neutrophils was explored using an in vitro HL-60 cell model.Results: LCN2mAb pretreatment had neuroprotective effects in mice. The expression of Ly6G was not significantly different, but the expression of N2 neutrophils was increased. In the in vitro study, LCN2mAb-treated N1-HL-60 cells induced N2-HL-60 polarization.Conclusion: LCN2 may affect the prognosis of ischemic stroke by mediating neutrophil polarization.","PeriodicalId":10456,"journal":{"name":"CNS & neurological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871527322666230417112850","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neutrophils and Lipocalin-2 (LCN2) play pivotal roles in cerebral ischemiareperfusion (I/R) injury. However, their contribution is not fully clarified.

Objective: This study aimed to explore the role of LCN2 and its association with neutrophil polarization in I/R injury.

Methods: A mouse model of middle cerebral artery occlusion (MCAO) was used to induce cerebral ischemia. LCN2mAb was administered 1 h and Anti-Ly6G was administered for 3d before MCAO. The role of LCN2 in the polarity transition of neutrophils was explored using an in vitro HL-60 cell model.

Results: LCN2mAb pretreatment had neuroprotective effects in mice. The expression of Ly6G was not significantly different, but the expression of N2 neutrophils was increased. In the in vitro study, LCN2mAb-treated N1-HL-60 cells induced N2-HL-60 polarization.

Conclusion: LCN2 may affect the prognosis of ischemic stroke by mediating neutrophil polarization.

查看原文本刊更多论文

脂联素-2 在中风后 N1/N2 中性粒细胞极化中的作用

背景：中性粒细胞和脂联素-2（LCN2）在脑缺血再灌注（I/R）损伤中起着关键作用。目的：本研究旨在探讨中性粒细胞和脂联素-2（LCN2）在脑缺血再灌注损伤中的作用：本研究旨在探讨 LCN2 在 I/R 损伤中的作用及其与中性粒细胞极化的关系：方法：采用大脑中动脉闭塞（MCAO）小鼠模型诱导脑缺血。MCAO前1小时注射LCN2mAb，3d注射抗Ly6G。利用体外 HL-60 细胞模型探讨了 LCN2 在中性粒细胞极性转换中的作用：结果：LCN2mAb预处理对小鼠神经有保护作用。Ly6G的表达无明显差异，但N2中性粒细胞的表达增加。在体外研究中，LCN2mAb 处理的 N1-HL-60 细胞诱导 N2-HL-60 极化：结论：LCN2 可通过介导中性粒细胞极化影响缺血性脑卒中的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS & neurological disorders drug targets 医学-神经科学

CiteScore

5.10

自引率

3.30%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.